---
id: hepatitis-d-virus_299
category: organisms
tags: [hepatitis-D, HDV, hepatitis-B, coinfection, superinfection, bulevirtide, cirrhosis]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Hepatitis D Virus (HDV)

**Q:** How do HDV coinfection and superinfection differ in outcomes, and what are the current treatment options?

**A:**

**Unique Biology:**
- **Defective virus** requiring HBV (HBsAg) for replication and transmission
- **Most severe form of chronic viral hepatitis**

**Coinfection vs Superinfection:**

| Feature | **Coinfection** (HDV + HBV simultaneous) | **Superinfection** (HDV infection in chronic HBV carrier) |
|---------|------------------------------------------|-----------------------------------------------------------|
| **Chronicity rate** | **<5%** (clears like acute HBV) | **70-90%** (usually becomes chronic) |
| **Outcome** | 95% clear both viruses | Rapid progression to severe disease |
| **Clinical course** | Self-limited acute hepatitis | Accelerated cirrhosis/HCC |

**Disease Severity:**
- **Cirrhosis**: 15% at 1-2 years, **70-80% at 5-10 years**
- **HCC/decompensation risk**: **2-3× higher** than HBV monoinfection
- HDV RNA-positive patients: **3.8× increased risk** of hepatic complications

**Epidemiology:**
- **0.8-1% general population**, **13-15% of HBsAg+ individuals** worldwide
- **3-5% of US hepatitis B population**

**Diagnosis:**
- **Anti-HDV antibodies** (screening)
- **HDV RNA** (confirms active viremia)

**Treatment:**

| Agent | Regimen | SVR24/Response |
|-------|---------|----------------|
| **Peginterferon α** | 180 μg SC weekly × 48 weeks | **29% SVR24** (monotherapy) |
| **Bulevirtide** (BLV) | **2 mg SC daily** (approved dose in Europe) | **45-48% combined response** (≥2 log decline + ALT normalization) |
| **BLV + PegIFNα** | Combination × 48 weeks | **32-46% SVR24** (dose-dependent) |

**Treatment Pearls:**
- Bulevirtide (entry inhibitor) approved in Europe 2020
- PegIFNα: 50% relapse rate at 5 years
- Combination therapy superior to monotherapy
- **NO HBV nucleos(t)ide analogs alone** (don't suppress HDV)

**Mnemonic - HDV "Super-Bad"**:
- **S**uperinfection → Stays (70-90% chronic)
- **B**ulevirtide → Best new option
- **A**ccelerated cirrhosis
- **D**efective virus (needs HBV)

**Pearl:** HDV superinfection of chronic HBV carriers has 70-90% chronicity and causes the most severe form of viral hepatitis. Bulevirtide represents first non-interferon treatment.

**Media:**

**Sources:** [PMC11850310 - HDV Therapeutic Options 2024], [PMC4208707 - Coinfection vs Superinfection], [WHO Hepatitis D Fact Sheet 2024], [StatPearls Hepatitis D NBK470436]
